Literature DB >> 10521252

Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: implications for design of signal-specific PTH ligands.

H Takasu1, T J Gardella, M D Luck, J T Potts, F R Bringhurst.   

Abstract

Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) activate the PTH/PTHrP receptor to trigger parallel increases in adenylyl cyclase (AC) and phospholipase C (PLC). The amino (N)-terminal region of PTH-(1-34) is essential for AC activation. Ligand domains required for activation of PLC, PKC, and other effectors have been less well-defined, although some studies in rodent systems have identified a core region [hPTH-(29-32)] involved in PKC activation. To determine the critical ligand domain(s) for PLC activation, a series of truncated hPTH-(1-34) analogues were assessed using LLC-PK1 cells that stably express abundant transfected human or rat PTH/PTHrP receptors. Phospholipase C signaling and ligand-binding affinity were reduced by carboxyl (C)-terminal truncation of hPTH-(1-34) but were coordinately restored when a binding-enhancing substitution (Glu(19) --> Arg(19)) was placed within hPTH-(1-28), the shortest hPTH peptide that could fully activate both AC and PLC. Phospholipase C, but not AC, activity was reduced by substituting Gly(1) for Ser(1) in hPTH-(1-34) and was eliminated entirely by removing either residue 1 or the alpha-amino group alone. These changes did not alter binding affinity. These findings led to design of an analogue, [Gly(1),Arg(19)]hPTH-(1-28), that was markedly signal-selective, with full AC but no PLC activity. Thus, the extreme N-terminus of hPTH constitutes a critical activation domain for coupling to PLC. The C-terminal region, especially hPTH-(28-31), contributes to PLC activation through effects upon receptor binding but is not required for full PLC activation. The N-terminal determinants of AC and PLC activation in hPTH-(1-34) overlap but are not identical, as subtle modifications in this region may dissociate activation of these two effectors. The [Gly(1),Arg(19)]hPTH-(1-28) analogue, in particular, should prove useful in dissociating AC- from PLC-dependent actions of PTH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521252     DOI: 10.1021/bi990437n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  26 in total

Review 1.  Interaction of PTH and PTHrP with their receptors.

Authors:  T J Gardella; H Jüppner
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 5.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

Review 6.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

7.  Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone.

Authors:  D Yang; R Singh; P Divieti; J Guo; M L Bouxsein; F R Bringhurst
Journal:  Bone       Date:  2007-02-16       Impact factor: 4.398

8.  The PTH-Gαs-protein kinase A cascade controls αNAC localization to regulate bone mass.

Authors:  Martin Pellicelli; Julie A Miller; Alice Arabian; Claude Gauthier; Omar Akhouayri; Joy Y Wu; Henry M Kronenberg; René St-Arnaud
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

9.  Negative regulation of parathyroid hormone (PTH)-activated phospholipase C by PTH/PTH-related peptide receptor phosphorylation and protein kinase A.

Authors:  Hesham A W Tawfeek; Abdul B Abou-Samra
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

10.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Authors:  Diane Gesty-Palmer; Ling Yuan; Bronwen Martin; William H Wood; Mi-Hye Lee; Michael G Janech; Lam C Tsoi; W Jim Zheng; Louis M Luttrell; Stuart Maudsley
Journal:  Mol Endocrinol       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.